1. Home
  2. ELDN vs TKNO Comparison

ELDN vs TKNO Comparison

Compare ELDN & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$3.60

Market Cap

291.8M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$7.27

Market Cap

268.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELDN
TKNO
Founded
2004
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
291.8M
268.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
ELDN
TKNO
Price
$3.60
$7.27
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
932.7K
223.8K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
30.67
43.86
EPS
N/A
N/A
Revenue
N/A
$40,520,000.00
Revenue This Year
N/A
$8.27
Revenue Next Year
N/A
$13.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.35
52 Week Low
$1.35
$1.91
52 Week High
$4.60
$7.84

Technical Indicators

Market Signals
Indicator
ELDN
TKNO
Relative Strength Index (RSI) 48.09 68.56
Support Level $3.31 $4.87
Resistance Level $3.96 N/A
Average True Range (ATR) 0.17 0.62
MACD 0.01 0.10
Stochastic Oscillator 56.00 79.03

Price Performance

Historical Comparison
ELDN
TKNO

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

Share on Social Networks: